Literature DB >> 8878605

Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network.

A E Simor1, M Louie, D E Low.   

Abstract

The antimicrobial susceptibilities of 1,089 clinical isolates of Streptococcus pneumoniae obtained from 39 laboratories across Canada between October 1994 and August 1995 were determined. A total of 91 isolates (8.4%) demonstrated intermediate resistance (MIC, 0.1 to 1.0 microgram/ml) and 36 (3.3%) had high-level resistance (MIC, > or = 2.0 micrograms/ml) to penicillin. Penicillin-resistant strains were more likely to have been recovered from normally sterile sites (P = 0.005) and to be cross-resistant to several beta-lactam and non-beta-lactam antimicrobial agents (P < 0.05). These results indicate that there has been a recent significant increase in the prevalence of antibiotic-resistant S. pneumoniae in Canada.

Entities:  

Mesh:

Year:  1996        PMID: 8878605      PMCID: PMC163497     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary.

Authors:  A Marton; M Gulyas; R Munoz; A Tomasz
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

2.  Detection and prevalence of pneumococci with increased resistance to penicillin.

Authors:  J M Dixon; A E Lipinski; M E Graham
Journal:  Can Med Assoc J       Date:  1977-11-19       Impact factor: 8.262

3.  Alterations in penicillin-binding proteins of clinical and laboratory isolates of pathogenic Streptococcus pneumoniae with low levels of penicillin resistance.

Authors:  S Handwerger; A Tomasz
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.

Authors:  P F Viladrich; C Cabellos; R Pallares; F Tubau; J Martínez-Lacasa; J Liñares; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Antibiotic-resistant pneumococcal disease in South African children.

Authors:  I R Friedland; K P Klugman
Journal:  Am J Dis Child       Date:  1992-08

Review 6.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

7.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

8.  Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

Authors:  T Mazzulli; A E Simor; R Jaeger; S Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

10.  Invasive pneumococcal disease in central Oklahoma: emergence of high-level penicillin resistance and multiple antibiotic resistance. Pneumococcus Study Group.

Authors:  L A Haglund; G R Istre; D A Pickett; D F Welch; D P Fine
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  29 in total

1.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2.

Authors:  J H Jorgensen; A L Barry; M M Traczewski; D F Sahm; M L McElmeel; S A Crawford
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

3.  A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens.

Authors:  R J Davidson; D E Low
Journal:  Can J Infect Dis       Date:  1999-03

Review 4.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Antibiotic resistance in Canada at the dawn of the new millennium - a model for the developed world?

Authors:  J M Conly; B L Johnston
Journal:  Can J Infect Dis       Date:  2000-09

6.  Routine adult immunization in Canada: recommendations and performance.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis       Date:  2002-07

7.  Antimicrobial resistance - Judicious use is the key.

Authors:  John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

8.  Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.

Authors:  Todd A Davies; Alan Evangelista; Sharon Pfleger; Karen Bush; Daniel F Sahm; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

9.  Determination of trimethoprim-sulfamethoxazole resistance in Streptococcus pneumoniae by using the E test with Mueller-Hinton agar supplemented with sheep or horse blood may be unreliable. The Pneumococcal Study Group.

Authors:  M Lovgren; L Dell'Acqua; R Palacio; G Echániz-Aviles; A Soto-Noguerón; E Castañeda; C I Agudelo; I Heitmann; M C Brandileone; R C Zanella; A Rossi; J Pace; J A Talbot
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.